76397927bf
- Source: inbox/queue/2026-05-05-anad-glp1-eating-disorder-guidance.md - Domain: health - Claims: 0, Entities: 0 - Enrichments: 4 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
4.3 KiB
| type | title | author | url | date | domain | secondary_domains | format | status | processed_by | processed_date | priority | tags | intake_tier | extraction_model | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| source | GLP-1 Medications and Eating Disorders: ANAD Clinical Guidance | ANAD (National Association of Anorexia Nervosa and Associated Disorders) | https://anad.org/glp-1-medications-eating-disorders/ | 2026-01-01 | health | article | processed | vida | 2026-05-05 | medium |
|
research-task | anthropic/claude-sonnet-4.5 |
Content
ANAD (professional organization) guidance on GLP-1 medications and eating disorders.
Overall position: "If you have a current or past eating disorder, please approach these medications with extreme caution and ensure you are working closely with a healthcare provider who understands eating disorders."
Evidence assessment: "We simply do not know if these medications will improve, worsen, or have no impact on eating disorder behaviors." Long-term safety/effectiveness "especially for those with an eating disorder — remain unclear."
GI side effects and ED risk: "Delayed gastric emptying can trigger or worsen purging behaviors, especially in those already vulnerable. Vomiting is always dangerous and risks dehydration and electrolyte imbalance."
Poison control: GLP-1 overdose calls have "tripled in recent years" — misuse pattern, not ED development.
Recommended screening BEFORE prescribing (no regulatory force):
- ED history including type, severity, stage of recovery, coexisting medical/mental health issues, past treatments
- Screen for: current restrictive eating behaviors, active bingeing or purging, severe body image issues, unstable recovery
No quantitative incidence data provided — "long-term research has yet to be done."
Multidisciplinary approach recommended: Physician + therapist + dietitian all versed in both GLP-1s and eating disorders before prescribing.
Agent Notes
Why this matters: ANAD is the authoritative professional society for eating disorders. Their guidance is the current clinical standard — and it's recommendation-only with zero regulatory force. The gap between recommended practice (tri-specialist team) and actual practice (no screening required, telehealth prescribing without any evaluation) is the operational measurement of the structural failure.
What surprised me: ANAD's epistemic honesty: "We simply do not know" is a strong acknowledgment of the evidence gap. This is the national professional society saying they don't have enough evidence to make a clear recommendation — which itself tells you something about the state of the field.
What I expected but didn't find: Any quantitative screening validation data. The SCOFF questionnaire and other screening tools exist but ANAD doesn't provide validation metrics here.
KB connections: SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3% and no operational infrastructure connects screening to action — exact parallel: ED screening is recommended, no reimbursement, no operational pathway.
Extraction hints: (1) ANAD recommendation vs. regulatory reality gap is itself a structural governance claim, (2) "Delayed gastric emptying can trigger or worsen purging in those already vulnerable" — confirms the "existing cycles" framing (not de novo), (3) Tri-specialist team recommendation as benchmark for what adequate clinical screening looks like.
Context: ANAD is the primary US professional and advocacy organization for eating disorders. Guidance is current as of 2026.
Curator Notes
PRIMARY CONNECTION: SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action
WHY ARCHIVED: ANAD guidance formalizes what "best practice" looks like (tri-specialist team + behavioral history) vs. what actually happens (no screening). The gap between recommended and actual practice is the operational measurement of the screening failure.
EXTRACTION HINT: The ANAD guidance + regulatory gap can support a structural claim: GLP-1 prescribing without mandatory ED screening creates population-scale risk because recommended practice (tri-specialist evaluation) has no enforcement mechanism or reimbursement pathway.